Spiral Therapeutics has secured additional funding

Aug 31, 2023

Our portfolio company Spiral Therapeutics has secured additional funding, led by Esperante & Ferring Ventures.

Spiral Therapeutics is a clinical-stage company focused on delivering therapies for inner ear disorders. Spiral’s novel drug delivery platform allows for minimally invasive, precise and durable exposure of drugs to the cochlea. Spiral is advancing a therapeutic pipeline with focus on hearing loss and balance disorders. Spiral’s lead program, SPT-2101, is a sustained-release steroid formulation for the treatment of inner ear inflammation.

This funding will accelerate their SPT-2101 clinical trials for Meniere’s Disease and the development of our hearing loss pipeline.

Hugo Peris, CEO of Spiral Therapeutics, said, “This fresh round of investment reflects the confidence in our unique drug delivery approach and technology, and strengthens our resolve to innovate in the field of neurotology. With the recent acquisition of Otonomy assets and our growing therapeutic pipeline, we are positioning Spiral as a forerunner in the field.”

Read the full press release here.